Evelyn Partners Investment Management LLP Grows Position in Eli Lilly and Company $LLY

Key Points

• Evelyn Partners Investment Management increased its Eli Lilly stake by 39.3% in the first quarter, bringing its holdings to 7,228 shares valued at approximately $6.65 million. Institutional investors collectively own 82.53% of the stock.
• Eli Lilly reported stronger-than-expected quarterly results, with EPS of $8.55 and revenue of $19.80 billion; revenue rose 55.5% year over year. The company issued fiscal 2026 EPS guidance of $35.50–$37.00.
• The stock was trading near its one-year high at $1,197.88, while analysts maintained a broadly positive outlook with a consensus “Moderate Buy” rating and an average price target of $1,283.64. Eli Lilly also declared a quarterly dividend of $1.73 per share.

Evelyn Partners Investment Management LLP increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 39.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,228 shares of the company's stock after acquiring an additional 2,040 shares during the quarter. Evelyn Partners Investment Management LLP's holdings in Eli Lilly and Company were worth $6,648,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of LLY. Brighton Jones LLC raised its stake in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its position in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after acquiring an additional 40 shares in the last quarter. Schnieders Capital Management LLC. increased its stake in Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company's stock worth $6,231,000 after acquiring an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC bought a new stake in Eli Lilly and Company during the second quarter worth approximately $356,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $749,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Up 0.2%

NYSE:LLY opened at $1,197.88 on Tuesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,249.45. The company has a 50-day moving average of $1,140.74 and a 200 day moving average of $1,041.08. The firm has a market cap of $1.13 trillion, a PE ratio of 42.55, a price-to-earnings-growth ratio of 1.48 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company's quarterly revenue was up 55.5% on a year-over-year basis. During the same period last year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 35.03 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 24.58%.

Wall Street Analyst Weigh In

LLY has been the topic of a number of analyst reports. Jefferies Financial Group boosted their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a "buy" rating in a research report on Tuesday, June 9th. BMO Capital Markets restated an "outperform" rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Guggenheim boosted their target price on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Sanford C. Bernstein increased their price target on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an "outperform" rating in a report on Tuesday, July 14th. Finally, Bank of America raised their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a research note on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $1,283.64.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.